Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
94 studies found for:    MPDL3280A
Show Display Options
Rank Status Study
1 Recruiting MPDL3280A-treatment-IST-UMCG
Conditions: Bladder Cancer;   Non Small Cell Lung Cancer;   Breast Cancer
Intervention: Drug: MPDL3280A
2 Recruiting Carboplatin Plus Etoposide With or Without MPDL3280A in Untreated Extensive Stage Small Cell Lung Cancer
Condition: Small Cell Lung Cancer ( SCLC )
Interventions: Drug: Carboplatin;   Drug: Etoposide;   Biological: MPDL3280A
3 Recruiting Preoperative MPDL3280A in Transitional Cell Carcinoma of the Bladder
Condition: Bladder Cancer
Intervention: Drug: MPDL3280A
4 Recruiting Triple-Negative First-Line Study: Neoadjuvant Trial of Nab-Paclitaxel and MPDL3280A, a Pdl-1 Inhibitor in Patients With Triple Negative Breast Cancer
Condition: Breast Cancer
Interventions: Drug: MPDL3280A;   Drug: Nab-paclitaxel
5 Recruiting MPDL3280A-imaging-IST-UMCG
Conditions: Breast Cancer;   Bladder Cancer;   Non Small Cell Lung Cancer
Intervention: Other: 89Zr-MPDL-3280A-PET scans
6 Recruiting A Single-Arm Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of MPDL3280A (Anti-PD-L1 Antibody) in Pediatric and Young Adult Participants With Solid Tumors
Condition: Solid Tumor
Intervention: Drug: MPDL3280A [TECENTRIQ]
7 Recruiting Neoadjuvant MPDL3280A, Nab-paclitaxel and Carboplatin (MAC) in NSCLC
Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: MPDL3280A;   Drug: Carboplatin;   Drug: Nab-paclitaxel
8 Active, not recruiting A Phase 1b/2 Study of Safety and Efficacy of Rociletinib in Combination With MPDL3280A in Patients With Advanced or Metastatic EGFR-mutant NSCLC
Condition: Non-small Cell Lung Cancer
Interventions: Drug: Rociletinib;   Drug: MPDL3280A
9 Recruiting MPDL3280A With Chemoradiation for Lung Cancer
Conditions: Lung Cancer;   Non-Small Cell Lung Cancer
Interventions: Drug: MPDL3280A;   Drug: Carboplatin;   Drug: Paclitaxel;   Radiation: Radiation Therapy
10 Recruiting A Pilot Study of MPDL3280A and HIGRT in Metastatic NSCLC
Condition: Non-small Cell Lung Cancer
Interventions: Drug: MPDL3280A;   Radiation: Hypofractionated Radiotherapy
11 Recruiting MPDL3280A and Stereotactic Ablative Radiotherapy in Patients With Non-small Cell Lung Cancer
Conditions: Recurrent Non-Small Cell Lung Carcinoma;   Stage IV Non-Small Cell Lung Cancer
Interventions: Drug: Anti-PD-L1 Monoclonal Antibody MPDL3280A;   Radiation: Stereotactic Body Radiation Therapy
12 Recruiting A Study to Assess the Safety and Tolerability of MPDL3280A in Combination With Other Immune-modulating Therapies in Patients With Locally Advanced or Metastatic Solid Tumors
Condition: Solid Cancers
Interventions: Drug: Interferon alfa-2b;   Drug: Ipilimumab;   Drug: MPDL3280A [TECENTRIQ]
13 Recruiting Study of MPDL3280A in Bladder Cancer
Condition: Carcinoma, Transitional Cell
Interventions: Drug: MPDL3280A Dose Level 1;   Drug: MPDL3280A Dose Level 2;   Drug: MPDL3280A Dose Level 3
14 Active, not recruiting A Study of Atezolizumab (MPDL3280A) Compared With Gemcitabine + Cisplatin or Carboplatin in Patients With Stage IV Squamous Non-Small Cell Lung Cancer [IMpower111]
Condition: Squamous Non-Small Cell Lung Cancer
Interventions: Drug: Atezolizumab (MPDL3280A) [TECENTRIQ];   Drug: Carboplatin;   Drug: Cisplatin;   Drug: Gemcitabine
15 Recruiting A Safety and Pharmacology Study of Atezolizumab (MPDL3280A) Administered With Obinutuzumab in Patients With Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma
Condition: Lymphoma
Interventions: Drug: Atezolizumab [TECENTRIQ];   Drug: Obinutuzumab
16 Recruiting A Study of RO7009789 in Combination With MPDL3280A in Patients With Locally Advanced and Metastatic Solid Tumors
Condition: Solid Cancers
Interventions: Drug: MPDL3280A [TECENTRIQ];   Drug: RO7009789
17 Recruiting A Study of Intravenous RO6895882 and MPDL3280A Combination in Patients With Locally Advanced and/or Metastatic Solid Tumors
Condition: Solid Cancers
Interventions: Drug: MPDL3280A [TECENTRIQ];   Drug: RO6895882
18 Recruiting A Phase 1b Study of Atezolizumab in Combination With Erlotinib or Alectinib in Participants With Non-Small Cell Lung Cancer
Condition: Non-Small Cell Lung Cancer
Interventions: Drug: Alectinib;   Drug: Atezolizumab;   Drug: Erlotinib
19 Recruiting Phase 2 Study of MPDL3280A Combined With CDX-1401 in NY-ESO 1 (+) IIIB, IV or Recurrent Non-Small Cell Lung Cancer
Condition: Non-Small Cell Lung Cancer
Interventions: Drug: CDX-1401;   Drug: MPDL3280A
20 Recruiting A Study of Atezolizumab (MPDL3280A) in Combination With Epacadostat (INCB024360) in Subjects With Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer and Previously Treated Stage IV Urothelial Carcinoma (INCB 24360-110 / ECHO-110)
Conditions: Non-small Cell Lung Cancer;   Urothelial Carcinoma
Interventions: Drug: atezolizumab;   Drug: epacadostat

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years